Skip to search formSkip to main contentSkip to account menu

sampatrilat

Known as: N-(1-(2-carboxy-3-(N(2)-mesyllysylamino)propyl)-1-cyclopentylcarbonyl)tyrosine 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Neprilysin (NEP) and angiotensin-converting enzyme (ACE) are two key zinc-dependent metallopeptidases in the natriuretic peptide… 
2020
2020
Several milk/whey derived peptides possess high in vitro angiotensin I-converting enzyme (ACE) inhibitory activity. However, in… 
2018
2018
Angiotensin‐1‐converting enzyme (ACE) is a zinc metallopeptidase that consists of two homologous catalytic domains (known as nACE… 
2016
2016
Sampatrilat is a vasopeptidase inhibitor that inhibits both angiotensin I-converting enzyme (ACE) and neutral endopeptidase. ACE… 
2003
2003
Sampatrilat is a novel vasopeptidase inhibitor that may offer a greater benefit than traditional angiotensin-converting enzyme… 
2002
2002
  • K. Allikmets
  • Current opinion in investigational drugs
  • 2002
  • Corpus ID: 36238587
Sampatrilat is a dual inhibitor of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE), which is under… 
1996
1996
1 The present studies compare the early renal response to (a) an endopeptidase‐24.11 (E‐24.11) inhibitor (candoxatrilat) (b) an…